ALG-1001

Novel DME treatment derives from multimodal activityALG-1001 is an integrin receptor inhibitor that acts to stabilize the retina’s response to diabetes-related hypoxic and oxidative stress, mitigating production of a host of molecules involved in the development of diabetic macular edema.
ALG-1001: Turning off the machinery of angiogenesisALG-1001 (Luminate, Allegro Ophthalmics) has a number of different mechanisms of action that benefit patients chronically treated with anti-vascular endothelial growth factor drugs and those who are treatment naïve.
Investigational pipeline for DME looks promisingPharmacotherapy research for diabetic macular edema is looking at targets other than VEGF inhibition to develop treatments that can be used as standalone intervention or may be complementary to current options.
Integrin peptide yields positive outcomes for VMA, VMT in phase II trialA new possible therapy for vitreomacular adhesion and vitreomacular traction had positive results in a phase II trial.
Integrin peptide trials continue for wet AMD, DME, other pathologiesThe first drug in the new class integrin peptide therapy continues to show continued efficacy and safety in various clinical trials.
Outlook for integrin peptide therapy
Outlook for integrin peptide therapyALG-1001 is the first of a new class of drugs, integrin peptide therapy, now going through clinical trials for patients with age-related macular degeneration, diabetic macular edema, and vitreomacular traction.
Phase II study begins for Allegro VMT treatmentAllegro Ophthalmics LLC has announced the start of a phase II study of ALG-1001 in patients with vitreomacular traction (VMT).
Phase II studies of integrin peptide drug approvedThe FDA has approved Allegro Ophthalmics’ investigational new drug application to begin phase II clinical studies of ALG-1001, an integrin peptide therapy.
Allegro gets FDA nod for Phase II studiesNew clinical trials underway for ALG-1001 in patients with wet AMD and symptomatic VMT.
Integrin peptide for AMD emergingIn the first clinical trial of ALG-1001 in wet AMD, there was an apparent clinical benefit to patients, as evidenced by improvements from baseline visual acuity and macular anatomy.